Inflammation and clinical presentation in neurodegenerative disease: A volatile relationship

Neurocase

Volumn 19, Issue 2, 2013, Pages 182-200

  Bettcher, Brianne Magouirk ^a   Kramer, Joel H ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Alzheimer's; Cognition; Inflammation; Neurodegenerative disease; Neuropsychology

Indexed keywords

ACUTE PHASE PROTEIN; ANTIINFLAMMATORY AGENT; APOLIPOPROTEIN E4; BIOLOGICAL MARKER; CYTOKINE; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 1;

ALZHEIMER DISEASE; AUTOPSY; CLINICAL FEATURE; CLINICAL TRIAL (TOPIC); COGNITION; COMORBIDITY; DEGENERATIVE DISEASE; DISEASE ASSOCIATION; FRONTOTEMPORAL DEMENTIA; HUMAN; INFLAMMATION; LONG TERM POTENTIATION; MILD COGNITIVE IMPAIRMENT; MINI MENTAL STATE EXAMINATION; NONHUMAN; PARKINSON DISEASE; POSITRON EMISSION TOMOGRAPHY; REVIEW; RISK;

COGNITION DISORDERS; ENCEPHALITIS; HUMANS; NEURODEGENERATIVE DISEASES; TIME FACTORS;

EID: 84876137517     PISSN: 13554794     EISSN: 14653656     Source Type: Journal    
DOI: 10.1080/13554794.2011.654227     Document Type: Review

References (153)

1. Alley, D. E., Crimmins, E. M., Karlamangla, A., Hu, P. and Seeman, T. E. 2008. Inflammation and rate of cognitive change in high-functioning older adults. Journal of Gerontology Series A: Biological Sciences and Medical Sciences, 63: 50-55.
2. Anan, F., Masaki, T., Shimomura, T., Fujiki, M., Umeno, Y., Eshima, N., Saikawa, T. and Yoshimatsu, H. 2011. High-sensitivity C-reactive protein is associated with hippocampus volume in nondementia patients with type 2 diabetes mellitus. Metabolism, 60: 460-466.
3. Arends, Y. M., Duyckaerts, C., Rozemuller, J. M., Eikelenboom, P. and Hauw, J. J. 2000. Microglia, amyloid and dementia in alzheimer disease. A correlative study. Neurobiology of Aging, 21: 39-47.
4. Arvanitakis, Z., Grodstein, F., Bienias, J. L., Schneider, J. A., Wilson, R. S., Kelly, J. F., Evans, D. A. and Bennett, D. A. 2008. Relation of NSAIDs to incident AD, change in cognitive function, and AD pathology. Neurology, 70: 2219-2225.
5. Baker, M., Mackenzie, I. R., Pickering-Brown, S. M., Gass, J., Rademakers, R., Lindholm, C., Snowden, J., Adamson, J., Sadovnick, A. D.Rollinson, S. 2006. Mutations in progranulin cause tau-negative frontotemporal dementia linked to chromosome 17. Nature, 442: 916-919.
6. Barger, S. W., Horster, D., Furukawa, K., Goodman, Y., Krieglstein, J. and Mattson, M. P. Tumor necrosis factors alpha and beta protect neurons against amyloid beta-peptide toxicity: Evidence for involvement of a kappa B-binding factor and attenuation of peroxide and Ca2+ accumulation. Proceedings of the National Academy of Sciences USA. Vol. 92, pp.9328-9332.
7. Becker, C., Jick, S. S. and Meier, C. R. 2011. NSAID use and risk of Parkinson disease: A population-based case-control study. European Journal of Neurology.,
8. Bermejo, P., Martin-Aragon, S., Benedi, J., Susin, C., Felici, E., Gil, P., Ribera, J. M. and Villar, A. M. 2008. Differences of peripheral inflammatory markers between mild cognitive impairment and Alzheimer's disease. Immunology Letters, 117: 198-202.
9. Bettcher, B. M., Wilheim, R., Rigby, T., Green, R., Miller, J. M., Racine, C. A., Yaffe, K., Miller, B. L. and Kramer, J. H. in press. C-Reactive protein is related to memory and medial temporal brain volume in older adults. Brain, Behavior, & Immunity.,
10. Blasko, I., Knaus, G., Weiss, E., Kemmler, G., Winkler, C., Falkensammer, G., Griesmacher, A., Wurzner, R., Marksteiner, J. and Fuchs, D. 2007. Cognitive deterioration in Alzheimer's disease is accompanied by increase of plasma neopterin. Journal of Psychiatric Research, 41: 694-701.
11. Blasko, I., Stampfer-Kountchev, M., Robatscher, P., Veerhuis, R., Eikelenboom, P. and Grubeck-Loebenstein, B. 2004. How chronic inflammation can affect the brain and support the development of Alzheimer's disease in old age: The role of microglia and astrocytes. Aging Cell, 3: 169-176.
12. Block, M. L. and Hong, J. S. 2007. Chronic microglial activation and progressive dopaminergic neurotoxicity. Biochemical Society Transactions, 35: 1127-1132.
13. Bonotis, K., Krikki, E., Holeva, V., Aggouridaki, C., Costa, V. and Baloyannis, S. 2008. Systemic immune aberrations in Alzheimer's disease patients. Journal of Neuroimmunology, 193: 183-187.
14. Bossu, P., Ciaramella, A., Moro, M. L., Bellincampi, L., Bernardini, S., Federici, G., Trequattrini, A., Macciardi, F., Spoletini, I.Di Iulio, F. 2007. Interleukin 18 gene polymorphisms predict risk and outcome of Alzheimer's disease. Journal of Neurology, Neurosurgery and Psychiatry, 78: 807-811.
15. Bossu, P., Ciaramella, A., Salani, F., Bizzoni, F., Varsi, E., Di Iulio, F., Giubilei, F., Gianni, W., Trequattrini, A.Moro, M. L. 2008. Interleukin-18 produced by peripheral blood cells is increased in Alzheimer's disease and correlates with cognitive impairment. Brain, Behavior, & Immunity, 22: 487-492.
16. Breitner, J. C., Baker, L. D., Montine, T. J., Meinert, C. L., Lyketsos, C. G., Ashe, K. H., Brandt, J., Craft, S., Evans, D. E.Green, R. C. 2011. Extended results of the Alzheimer's disease anti-inflammatory prevention trial. Alzheimer's Dementia, 7: 402-411.
17. Buchhave, P., Janciauskiene, S., Zetterberg, H., Blennow, K., Minthon, L. and Hansson, O. 2009. Elevated plasma levels of soluble CD40 in incipient Alzheimer's disease. Neuroscience Letters, 450: 56-59.
18. Cagnin, A., Brooks, D. J., Kennedy, A. M., Gunn, R. N., Myers, R., Turkheimer, F. E., Jones, T. and Banati, R. B. 2001. In-vivo measurement of activated microglia in dementia. Lancet, 358: 461-467.
19. Cagnin, A., Rossor, M., Sampson, E. L., Mackinnon, T. and Banati, R. B. 2004. In vivo detection of microglial activation in frontotemporal dementia. Annals of Neurology, 56: 894-897.
20. Chen, H., Jacobs, E., Schwarzschild, M. A., McCullough, M. L., Calle, E. E., Thun, M. J. and Ascherio, A. 2005. Nonsteroidal antiinflammatory drug use and the risk for Parkinson's disease. Annals of Neurology, 58: 963-967.
21. Chen, H., O'Reilly, E. J., Schwarzschild, M. A. and Ascherio, A. 2008. Peripheral inflammatory biomarkers and risk of Parkinson's disease. American Journal of Epidemiology, 167: 90-95.
22. Chen, H., Zhang, S. M., Hernan, M. A., Schwarzschild, M. A., Willett, W. C., Colditz, G. A., Speizer, F. E. and Ascherio, A. 2003. Nonsteroidal anti-inflammatory drugs and the risk of Parkinson disease. Archives of Neurology, 60: 1059-1064.
23. Chen, J., Buchanan, J. B., Sparkman, N. L., Godbout, J. P., Freund, G. G. and Johnson, R. W. 2008b. Neuroinflammation and disruption in working memory in aged mice after acute stimulation of the peripheral innate immune system. Brain, Behavior, & Immunity, 22: 301-311.
24. Cunningham, C. 2011. Systemic inflammation and delirium: Important co-factors in the progression of dementia. Biochemical Society Transactions, 39: 945-953.
25. Cunningham, C., Campion, S., Lunnon, K., Murray, C. L., Woods, J. F., Deacon, R. M., Rawlins, J. N. and Perry, V. H. 2009. Systemic inflammation induces acute behavioral and cognitive changes and accelerates neurodegenerative disease. Biological Psychiatry, 65: 304-312.
26. Dickerson, B. C., Stoub, T. R., Shah, R. C., Sperling, R. A., Killiany, R. J., Albert, M. S., Hyman, B. T., Blacker, D. and Detoledo-Morrell, L. 2011. Alzheimer-signature MRI biomarker predicts AD dementia in cognitively normal adults. Neurology, 76: 1395-1402.
27. Dik, M. G., Jonker, C., Hack, C. E., Smit, J. H., Comijs, H. C. and Eikelenboom, P. 2005. Serum inflammatory proteins and cognitive decline in older persons. Neurology, 64: 1371-1377.
28. Dimopoulos, N., Piperi, C., Salonicioti, A., Mitropoulos, P., Kallai, E., Liappas, I., Lea, R. W. and Kalofoutis, A. 2006. Indices of low-grade chronic inflammation correlate with early cognitive deterioration in an elderly Greek population. Neuroscience Letters, 398: 118-123.
29. Diniz, B. S., Teixeira, A. L., Ojopi, E. B., Talib, L. L., Mendonca, V. A., Gattaz, W. F. and Forlenza, O. V. 2010. Higher serum sTNFR1 level predicts conversion from mild cognitive impairment to Alzheimer's disease. Journal of Alzheimer's Disease, 22: 1305-1311.
30. Driver, J. A., Logroscino, G., Lu, L., Gaziano, J. M. and Kurth, T. 2011. Use of non-steroidal anti-inflammatory drugs and risk of Parkinson's disease: Nested case-control study. British Medical Journal, 342: d198
31. Dufek, M., Hamanova, M., Lokaj, J., Goldemund, D., Rektorova, I., Michalkova, Z., Sheardova, K. and Rektor, I. 2009. Serum inflammatory biomarkers in Parkinson's disease. Parkinsonism & Related Disorders, 15: 318-320.
32. Eikelenboom, P., Rozemuller, J. M. and van Muiswinkel, F. L. 1998. Inflammation and Alzheimer's disease: Relationships between pathogenic mechanisms and clinical expression. Experimental Neurology, 154: 89-98.
33. Ekdahl, C. T., Kokaia, Z. and Lindvall, O. 2009. Brain inflammation and adult neurogenesis: The dual role of microglia. Neuroscience, 158: 1021-1029.
34. Engelhart, M. J., Geerlings, M. I., Meijer, J., Kiliaan, A., Ruitenberg, A., van Swieten, J. C., Stijnen, T., Hofman, A., Witteman, J. C. and Breteler, M. M. 2004. Inflammatory proteins in plasma and the risk of dementia: The rotterdam study. Archives of Neurology, 61: 668-672.
35. Fong, T. G., Jones, R. N., Shi, P., Marcantonio, E. R., Yap, L., Rudolph, J. L., Yang, F. M., Kiely, D. K. and Inouye, S. K. 2009. Delirium accelerates cognitive decline in Alzheimer disease. Neurology, 72: 1570-1575.
36. Forlenza, O. V., Diniz, B. S., Talib, L. L., Mendonca, V. A., Ojopi, E. B., Gattaz, W. F. and Teixeira, A. L. 2009. Increased serum IL-1beta level in Alzheimer's disease and mild cognitive impairment. Dementia and Geriatric Cognitive Disorders, 28: 507-512.
37. Gagne, J. J. and Power, M. C. 2010. Anti-inflammatory drugs and risk of Parkinson disease: A meta-analysis. Neurology, 74: 995-1002.
38. Galimberti, D., Fenoglio, C. and Scarpini, E. 2008. Inflammation in neurodegenerative disorders: Friend or foe?. Current Aging Science, 1: 30-41.
39. Galimberti, D., Schoonenboom, N., Scheltens, P., Fenoglio, C., Venturelli, E., Pijnenburg, Y. A., Bresolin, N. and Scarpini, E. 2006. Intrathecal chemokine levels in Alzheimer disease and frontotemporal lobar degeneration. Neurology, 66: 146-147.
40. Galimberti, D., Venturelli, E., Fenoglio, C., Guidi, I., Villa, C., Bergamaschini, L., Cortini, F., Scalabrini, D., Baron, P., Vergani, C., Bresolin, N. and Scarpini, E. 2008. Intrathecal levels of IL-6, IL-11 and LIF in Alzheimer's disease and frontotemporal lobar degeneration. Journal of Neurology, 255: 539-544.
41. Gao, X., Chen, H., Schwarzschild, M. A. and Ascherio, A. 2011. Use of ibuprofen and risk of Parkinson disease. Neurology, 76: 863-869.
42. Gardet, A., Benita, Y., Li, C., Sands, B. E., Ballester, I., Stevens, C., Korzenik, J. R., Rioux, J. D., Daly, M. J., Xavier, R. J. and Podolsky, D. K. 2010. LRRK2 is involved in the IFN-gamma response and host response to pathogens. Journal of Immunology, 185: 5577-5585.
43. Gerhard, A., Pavese, N., Hotton, G., Turkheimer, F., Es, M., Hammers, A., Eggert, K., Oertel, W., Banati, R. B. and Brooks, D. J. 2006. In vivo imaging of microglial activation with [11C](R)-PK11195 PET in idiopathic Parkinson's disease. Neurobiology of Disease, 21: 404-412.
44. Gimeno, D., Marmot, M. G. and Singh-Manoux, A. 2008. Inflammatory markers and cognitive function in middle-aged adults: The Whitehall II study. Psychoneuroendocrinology, 33: 1322-1334.
45. Giunta, S. 2008. Exploring the complex relations between inflammation and aging (inflamm-aging): Anti-inflamm-aging remodelling of inflamm-aging, from robustness to frailty. Inflammation Research, 57: 558-563.
46. Glass, C. K., Saijo, K., Winner, B., Marchetto, M. C. and Gage, F. H. 2010. Mechanisms underlying inflammation in neurodegeneration. Cell, 140: 918-934.
47. Gorelick, P. B. 2010. Role of inflammation in cognitive impairment: Results of observational epidemiological studies and clinical trials. Annals of the New York Academy of Sciences, 1207: 155-162.
48. Grammas, P. and Ovase, R. 2001. Inflammatory factors are elevated in brain microvessels in Alzheimer's disease. Neurobiology of Aging, 22: 837-842.
49. Grilli, M., Goffi, F., Memo, M. and Spano, P. 1996. Interleukin-1beta and glutamate activate the NF-kappaB/Rel binding site from the regulatory region of the amyloid precursor protein gene in primary neuronal cultures. The Journal of Biological Chemistry, 271: 15002-15007.
50. Gunstad, J., Bausserman, L., Paul, R. H., Tate, D. F., Hoth, K., Poppas, A., Jefferson, A. L. and Cohen, R. A. 2006. C-reactive protein, but not homocysteine, is related to cognitive dysfunction in older adults with cardiovascular disease. Journal of Clinical Neuroscience, 13: 540-546.
51. Hassin-Baer, S., Cohen, O. S., Vakil, E., Molshazki, N., Sela, B. A., Nitsan, Z., Chapman, J. and Tanne, D. 2011. Is C-reactive protein level a marker of advanced motor and neuropsychiatric complications in Parkinson's disease?. Journal of Neural Transmission, 118: 539-543.
52. Hayden, K. M., Zandi, P. P., Khachaturian, A. S., Szekely, C. A., Fotuhi, M., Norton, M. C., Tschanz, J. T., Pieper, C. F., Corcoran, C.Lyketsos, C. G. 2007. Does NSAID use modify cognitive trajectories in the elderly? The Cache County study. Neurology, 69: 275-282.
53. Hernan, M. A., Logroscino, G. and Garcia Rodriguez, L. A. 2006. Nonsteroidal anti-inflammatory drugs and the incidence of Parkinson disease. Neurology, 66: 1097-1099.
54. Herrera, A. J., Castano, A., Venero, J. L., Cano, J. and Machado, A. 2000. The single intranigral injection of LPS as a new model for studying the selective effects of inflammatory reactions on dopaminergic system. Neurobiology of Disease, 7: 429-447.
55. Holmes, C., Cunningham, C., Zotova, E., Culliford, D. and Perry, V. H. 2011. Proinflammatory cytokines, sickness behavior, and Alzheimer disease. Neurology, 77: 212-218.
56. Holmes, C., Cunningham, C., Zotova, E., Woolford, J., Dean, C., Kerr, S., Culliford, D. and Perry, V. H. 2009. Systemic inflammation and disease progression in Alzheimer disease. Neurology, 73: 768-774.
57. Holmes, C., El-Okl, M., Williams, A. L., Cunningham, C., Wilcockson, D. and Perry, V. H. 2003. Systemic infection, interleukin 1beta, and cognitive decline in Alzheimer's disease. Journal of Neurology, Neurosurgery and Psychiatry, 74: 788-789.
58. Hoozemans, J. J., Veerhuis, R., Rozemuller, J. M. and Eikelenboom, P. 2006. Neuroinflammation and regeneration in the early stages of Alzheimer's disease pathology. International Journal of Developmental Neuroscience, 24: 157-165.
59. Hoth, K. F., Haley, A. P., Gunstad, J., Paul, R. H., Poppas, A., Jefferson, A. L., Tate, D. F., Ono, M., Jerskey, B. A. and Cohen, R. A. 2008. Elevated C-reactive protein is related to cognitive decline in older adults with cardiovascular disease. Journal of the American Geriatric Society, 56: 1898-1903.
60. in t' Veld, B. A., Ruitenberg, A., Hofman, A., Launer, L. J., van Duijn, C. M., Stijnen, T., Breteler, M. M. and Stricker, B. H. 2001. Nonsteroidal antiinflammatory drugs and the risk of Alzheimer's disease. New England Journal of Medicine, 345: 1515-1521.
61. Jefferson, A. L., Massaro, J. M., Wolf, P. A., Seshadri, S., Au, R., Vasan, R. S., Larson, M. G., Meigs, J. B., Keaney, J. F. JrLipinska, I. 2007. Inflammatory biomarkers are associated with total brain volume: The Framingham Heart Study. Neurology, 68: 1032-1038.
62. Kim, T. S., Lim, H. K., Lee, J. Y., Kim, D. J., Park, S., Lee, C. and Lee, C. U. 2008. Changes in the levels of plasma soluble fractalkine in patients with mild cognitive impairment and Alzheimer's disease. Neuroscience Letters, 436: 196-200.
63. Komulainen, P., Lakka, T. A., Kivipelto, M., Hassinen, M., Penttila, I. M., Helkala, E. L., Gylling, H., Nissinen, A. and Rauramaa, R. 2007. Serum high sensitivity C-reactive protein and cognitive function in elderly women. Age and Ageing, 36: 443-448.
64. Kravitz, B. A., Corrada, M. M. and Kawas, C. H. 2009. Elevated C-reactive protein levels are associated with prevalent dementia in the oldest-old. Alzheimer's & Dementia, 5: 318-323.
65. Kurkowska-Jastrzebska, I., Litwin, T., Joniec, I., Ciesielska, A., Przybylkowski, A., Czlonkowski, A. and Czlonkowska, A. 2004. Dexamethasone protects against dopaminergic neurons damage in a mouse model of Parkinson's disease. International Immunopharmacology, 4: 1307-1318.
66. Leoutsakos, J. M., Muthen, B. O., Breitner, J. C. and Lyketsos, C. G. 2011. Effects of non-steroidal anti-inflammatory drug treatments on cognitive decline vary by phase of pre-clinical Alzheimer disease: Findings from the randomized controlled Alzheimer's Disease Anti-inflammatory Prevention Trial. International Journal of Geriatric Psychiatry.,
67. Letiembre, M., Liu, Y., Walter, S., Hao, W., Pfander, T., Wrede, A., Schulz-Schaeffer, W. and Fassbender, K. 2009. Screening of innate immune receptors in neurodegenerative diseases: A similar pattern. Neurobiology of Aging, 30: 759-768.
68. Licastro, F., Pedrini, S., Caputo, L., Annoni, G., Davis, L. J., Ferri, C., Casadei, V. and Grimaldi, L. M. 2000. Increased plasma levels of interleukin-1, interleukin-6 and alpha-1-antichymotrypsin in patients with Alzheimer's disease: Peripheral inflammation or signals from the brain?. Journal of Neuroimmunology, 103: 97-102.
69. Lin, H. B., Yang, X. M., Li, T. J., Cheng, Y. F., Zhang, H. T. and Xu, J. P. 2009. Memory deficits and neurochemical changes induced by C-reactive protein in rats: Implication in Alzheimer's disease. Psychopharmacology (Berlin), 204: 705-714.
70. Lindberg, C., Chromek, M., Ahrengart, L., Brauner, A., Schultzberg, M. and Garlind, A. 2005. Soluble interleukin-1 receptor type II, IL-18 and caspase-1 in mild cognitive impairment and severe Alzheimer's disease. Neurochemistry International, 46: 551-557.
71. Liu, B. and Hong, J. S. 2003. Role of microglia in inflammation-mediated neurodegenerative diseases: Mechanisms and strategies for therapeutic intervention. Journal of Pharmacology and Experimental Therapeutics, 304: 1-7.
72. Locascio, J. J., Fukumoto, H., Yap, L., Bottiglieri, T., Growdon, J. H., Hyman, B. T. and Irizarry, M. C. 2008. Plasma amyloid beta-protein and C-reactive protein in relation to the rate of progression of Alzheimer disease. Archives of Neurology, 65: 776-785.
73. Lyketsos, C. G., Breitner, J. C., Green, R. C., Martin, B. K., Meinert, C., Piantadosi, S. and Sabbagh, M. 2007. Naproxen and celecoxib do not prevent AD in early results from a randomized controlled trial. Neurology, 68: 1800-1808.
74. MacLullich, A. M. and Hall, R. J. 2011. Who understands delirium?. Age and Ageing, 40: 412-414.
75. Mancinella, A., Mancinella, M., Carpinteri, G., Bellomo, A., Fossati, C., Gianturco, V., Iori, A., Ettorre, E., Troisi, G. and Marigliano, V. 2009. Is there a relationship between high C-reactive protein (CRP) levels and dementia?. Archives of Gerontology and Geriatrics, 49(1): 185-194.
76. Marioni, R. E., Stewart, M. C., Murray, G. D., Deary, I. J., Fowkes, F. G., Lowe, G. D., Rumley, A. and Price, J. F. 2009. Peripheral levels of fibrinogen, C-reactive protein, and plasma viscosity predict future cognitive decline in individuals without dementia. Psychosomatic Medicine, 71: 901-906.
77. Marsland, A. L., Petersen, K. L., Sathanoori, R., Muldoon, M. F., Neumann, S. A., Ryan, C., Flory, J. D. and Manuck, S. B. 2006. Interleukin-6 covaries inversely with cognitive performance among middle-aged community volunteers. Psychosomatic Medicine, 68: 895-903.
78. Martin, B. K., Szekely, C., Brandt, J., Piantadosi, S., Breitner, J. C., Craft, S., Evans, D., Green, R. and Mullan, M. 2008. Cognitive function over time in the Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT): Results of a randomized, controlled trial of naproxen and celecoxib. Archives of Neurology, 65: 896-905.
79. McGeer, E. G. and McGeer, P. L. 2001. Innate immunity in Alzheimer's disease: A model for local inflammatory reactions. Molecular Interventions, 1: 22-29.
80. McGeer, E. G. and McGeer, P. L. 2007. The role of anti-inflammatory agents in Parkinson's disease. CNS Drugs, 21: 789-797.
81. McGeer, P. L. and McGeer, E. G. 1995. The inflammatory response system of brain: Implications for therapy of Alzheimer and other neurodegenerative diseases. Brain Research and Brain Research Reviews, 21: 195-218.
82. McGeer, P. L. and McGeer, E. G. 2004. Inflammation and neurodegeneration in Parkinson's disease. Parkinsonism & Related Disorders, 10(1): S3-7.
83. McGeer, P. L. and McGeer, E. G. 2008. Glial reactions in Parkinson's disease. Movement Disorders, 23: 474-483.
84. McGeer, P. L., Rogers, J. and McGeer, E. G. 2006. Inflammation, anti-inflammatory agents and Alzheimer disease: The last 12 years. Journal of Alzheimer's Disease, 9: 271-276.
85. Menza, M., Dobkin, R. D., Marin, H., Mark, M. H., Gara, M., Bienfait, K., Dicke, A. and Kusnekov, A. 2010. The role of inflammatory cytokines in cognition and other non-motor symptoms of Parkinson's disease. Psychosomatics, 51: 474-479.
86. Motta, M., Imbesi, R., Di Rosa, M., Stivala, F. and Malaguarnera, L. 2007. Altered plasma cytokine levels in Alzheimer's disease: Correlation with the disease progression. Immunology Letters, 114: 46-51.
87. Murphy, G. M. Jr, Claassen, J. D., DeVoss, J. J., Pascoe, N., Taylor, J., Tinklenberg, J. R. and Yesavage, J. A. 2001. Rate of cognitive decline in AD is accelerated by the interleukin-1 alpha -889 *1 allele. Neurology, 56: 1595-1597.
88. Murray, C. A. and Lynch, M. A. 1998. Evidence that increased hippocampal expression of the cytokine interleukin-1 beta is a common trigger for age- and stress-induced impairments in long-term potentiation. Journal of Neuroscience, 18: 2974-2981.
89. Murray, C., Sanderson, D. J., Barkus, C., Deacon, R. M., Rawlins, J. N., Bannerman, D. M. and Cunningham, C. 2012. Systemic inflammation induces acute working memory deficits in the primed brain: Relevance for delirium. Neurobiology of Aging, 33(3): 603-616.
90. Murray, C. L., Skelly, D. T. and Cunningham, C. 2011. Exacerbation of CNS inflammation and neurodegeneration by systemic LPS treatment is independent of circulating IL-1beta and IL-6. Journal of Neuroinflammation, 8: 50
91. Noble, J. M., Manly, J. J., Schupf, N., Tang, M. X., Mayeux, R. and Luchsinger, J. A. 2010. Association of C-reactive protein with cognitive impairment. Archives of Neurology, 67: 87-92.
92. Okello, A., Edison, P., Archer, H. A., Turkheimer, F. E., Kennedy, J., Bullock, R., Walker, Z., Kennedy, A., Fox, N., Rossor, M. and Brooks, D. J. 2009. Microglial activation and amyloid deposition in mild cognitive impairment: A PET study. Neurology, 72: 56-62.
93. Olgiati, P., Politis, A., Malitas, P., Albani, D., Dusi, S., Polito, L., De Mauro, S., Zisaki, A., Piperi, C.Stamouli, E. 2010. APOE epsilon-4 allele and cytokine production in Alzheimer's disease. International Journal of Geriatric Psychiatry, 25: 338-344.
94. Ozturk, C., Ozge, A., Yalin, O. O., Yilmaz, I. A., Delialioglu, N., Yildiz, C., Tesdelen, B. and Kudiaki, C. 2007. The diagnostic role of serum inflammatory and soluble proteins on dementia subtypes: Correlation with cognitive and functional decline. Behavioral Neurology, 18: 207-215.
95. Parachikova, A., Agadjanyan, M. G., Cribbs, D. H., Blurton-Jones, M., Perreau, V., Rogers, J., Beach, T. G. and Cotman, C. W. 2007. Inflammatory changes parallel the early stages of Alzheimer disease. Neurobiology of Aging, 28: 1821-1833.
96. Pawelec, G., Barnett, Y., Forsey, R., Frasca, D., Globerson, A., McLeod, J., Caruso, C., Franceschi, C., Fulop, T.Gupta, S. 2002. T cells and aging, January 2002 update. Front Bioscience, 7: d1056-1183.
97. Perry, R. J., Graham, A., Williams, G., Rosen, H., Erzinclioglu, S., Weiner, M., Miller, B. and Hodges, J. 2006. Patterns of frontal lobe atrophy in frontotemporal dementia: A volumetric MRI study. Dementia and Geriatric Cognitive Disorders, 22: 278-287.
98. Perry, R. T., Collins, J. S., Wiener, H., Acton, R. and Go, R. C. 2001. The role of TNF and its receptors in Alzheimer's disease. Neurobiology of Aging, 22: 873-883.
99. Perry, V. H., Cunningham, C. and Holmes, C. 2007. Systemic infections and inflammation affect chronic neurodegeneration. Nature Reviews Immunology, 7: 161-167.
100. Piehl, F. and Olsson, T. 2009. Inflammation and susceptibility to neurodegeneration: The use of unbiased genetics to decipher critical regulatory pathways. Neuroscience, 158: 1143-1150.
101. Popp, J., Bacher, M., Kolsch, H., Noelker, C., Deuster, O., Dodel, R. and Jessen, F. 2009. Macrophage migration inhibitory factor in mild cognitive impairment and Alzheimer's disease. Journal of Psychiatric Research, 43: 749-753.
102. Przedborski, S. 2010. Inflammation and Parkinson's disease pathogenesis. Movement Disorders, 25(1): S55-57.
103. Rabinovici, G. D., Seeley, W. W., Kim, E. J., Gorno-Tempini, M. L., Rascovsky, K., Pagliaro, T. A., Allison, S. C., Halabi, C., Kramer, J. H.Johnson, J. K. 2007. Distinct MRI atrophy patterns in autopsy-proven Alzheimer's disease and frontotemporal lobar degeneration. American Journal of Alzheimer's Disease and Other Dementias, 22: 474-488.
104. Rafnsson, S. B., Deary, I. J., Smith, F. B., Whiteman, M. C., Rumley, A., Lowe, G. D. and Fowkes, F. G. 2007. Cognitive decline and markers of inflammation and hemostasis: The Edinburgh Artery Study. Journal of the American Geriatric Society, 55: 700-707.
105. Rainero, I., Rubino, E., Cappa, G., Rota, E., Valfre, W., Ferrero, P., Fenoglio, P., Baci, D., D'Amico, G.Vaula, G. 2009. Pro-inflammatory cytokine genes influence the clinical features of frontotemporal lobar degeneration. Dementia and Geriatric Cognitive Disorders, 27: 543-547.
106. Ravaglia, G., Forti, P., Maioli, F., Chiappelli, M., Montesi, F., Tumini, E., Mariani, E., Licastro, F. and Patterson, C. 2007. Blood inflammatory markers and risk of dementia: The Conselice Study of Brain Aging. Neurobiology of Aging, 28: 1810-1820.
107. Ravina, B., Tanner, C., Dieuliis, D., Eberly, S., Flagg, E., Galpern, W. R., Fahn, S., Goetz, C. G., Grate, S.Kurlan, R. 2009. A longitudinal program for biomarker development in Parkinson's disease: A feasibility study. Movement Disorders, 24: 2081-2090.
108. Reale, M., Iarlori, C., Thomas, A., Gambi, D., Perfetti, B., Di Nicola, M. and Onofrj, M. 2009. Peripheral cytokines profile in Parkinson's disease. Brain, Behavior, & Immunity, 23: 55-63.
109. Rentzos, M., Nikolaou, C., Andreadou, E., Paraskevas, G. P., Rombos, A., Zoga, M., Tsoutsou, A., Boufidou, F., Kapaki, E. and Vassilopoulos, D. 2009. Circulating interleukin-10 and interleukin-12 in Parkinson's disease. Acta Neurologica Scandinavica, 119: 332-337.
110. Rentzos, M., Paraskevas, G. P., Kapaki, E., Nikolaou, C., Zoga, M., Rombos, A., Tsoutsou, A. and Vassilopoulos, D. D. 2006. Interleukin-12 is reduced in cerebrospinal fluid of patients with Alzheimer's disease and frontotemporal dementia. Journal of Neurology Science, 249: 110-114.
111. Rentzos, M., Zoga, M., Paraskevas, G. P., Kapaki, E., Rombos, A., Nikolaou, C., Tsoutsou, A. and Vassilopoulos, D. 2006. IL-15 is elevated in cerebrospinal fluid of patients with Alzheimer's disease and frontotemporal dementia. Journal of Geriatric Psychiatry and Neurology, 19: 114-117.
112. Roberts, R. O., Geda, Y. E., Knopman, D. S., Boeve, B. F., Christianson, T. J., Pankratz, V. S., Kullo, I. J., Tangalos, E. G., Ivnik, R. J. and Petersen, R. C. 2009. Association of C-reactive protein with mild cognitive impairment. Alzheimer's Dementia, 5: 398-405.
113. Rogers, J., Mastroeni, D., Leonard, B., Joyce, J. and Grover, A. 2007. Neuroinflammation in Alzheimer's disease and Parkinson's disease: Are microglia pathogenic in either disorder?. International Review of Neurobiology, 82: 235-246.
114. Rudin, E. and Barzilai, N. 2005. Inflammatory peptides derived from adipose tissue. Immunity & Ageing, 2: 1
115. Sala, G., Galimberti, G., Canevari, C., Raggi, M. E., Isella, V., Facheris, M., Appollonio, I. and Ferrarese, C. 2003. Peripheral cytokine release in Alzheimer patients: Correlation with disease severity. Neurobiology of Aging, 24: 909-914.
116. Salmon, D. P. and Filoteo, J. V. 2007. Neuropsychology of cortical versus subcortical dementia syndromes. Semininar in Neurology, 27: 7-21.
117. Scali, C., Prosperi, C., Bracco, L., Piccini, C., Baronti, R., Ginestroni, A., Sorbi, S., Pepeu, G. and Casamenti, F. 2002. Neutrophils CD11b and fibroblasts PGE(2) are elevated in Alzheimer's disease. Neurobiology of Aging, 23: 523-530.
118. Scalzo, P., Kummer, A., Cardoso, F. and Teixeira, A. L. 2010. Serum levels of interleukin-6 are elevated in patients with Parkinson's disease and correlate with physical performance. Neuroscience Letters, 468: 56-58.
119. Schmidt, R., Schmidt, H., Curb, J. D., Masaki, K., White, L. R. and Launer, L. J. 2002. Early inflammation and dementia: A 25-year follow-up of the Honolulu-Asia Aging Study. Annals of Neurology, 52: 168-174.
120. Schram, M. T., Euser, S. M., de Craen, A. J., Witteman, J. C., Frolich, M., Hofman, A., Jolles, J., Breteler, M. M. and Westendorp, R. G. 2007. Systemic markers of inflammation and cognitive decline in old age. Journal of the American Geriatric Society, 55: 708-716.
121. Schuitemaker, A., Dik, M. G., Veerhuis, R., Scheltens, P., Schoonenboom, N. S., Hack, C. E., Blankenstein, M. A. and Jonker, C. 2009. Inflammatory markers in AD and MCI patients with different biomarker profiles. Neurobiology of Aging, 30: 1885-1889.
122. Semmler, A., Okulla, T., Sastre, M., Dumitrescu-Ozimek, L. and Heneka, M. T. 2005. Systemic inflammation induces apoptosis with variable vulnerability of different brain regions. Journal of Chemical Neuroanatomy, 30: 144-157.
123. Sheng, J. G., Zhu, S. G., Jones, R. A., Griffin, W. S. and Mrak, R. E. 2000. Interleukin-1 promotes expression and phosphorylation of neurofilament and tau proteins in vivo. Experimental Neurology, 163: 388-391.
124. Sjogren, M., Folkesson, S., Blennow, K. and Tarkowski, E. 2004. Increased intrathecal inflammatory activity in frontotemporal dementia: Pathophysiological implications. Journal of Neurology, Neurosurgery and Psychiatry, 75: 1107-1111.
125. Solerte, S. B., Cravello, L., Ferrari, E. and Fioravanti, M. 2000. Overproduction of IFN-gamma and TNF-alpha from natural killer (NK) cells is associated with abnormal NK reactivity and cognitive derangement in Alzheimer's disease. Annals of the New York Academy of Sciences, 917: 331-340.
126. Song, I. U., Chung, S. W., Kim, J. S. and Lee, K. S. 2011. Association between high-sensitivity C-reactive protein and risk of early idiopathic Parkinson's disease. Neurological Sciences, 32: 31-34.
127. Sprague, A. H. and Khalil, R. A. 2009. Inflammatory cytokines in vascular dysfunction and vascular disease. Biochemical Pharmacology, 78: 539-552.
128. Sundelof, J., Kilander, L., Helmersson, J., Larsson, A., Ronnemaa, E., Degerman-Gunnarsson, M., Basun, H., Lannfelt, L. and Basu, S. 2009. Systemic inflammation and the risk of Alzheimer's disease and dementia: A prospective population-based study. Journal of Alzheimer's Disease, 18: 79-87.
129. Swardfager, W., Lanctot, K., Rothenburg, L., Wong, A., Cappell, J. and Herrmann, N. 2010. A meta-analysis of cytokines in Alzheimer's disease. Biological Psychiatry, 68: 930-941.
130. Tan, Z. S., Beiser, A. S., Vasan, R. S., Roubenoff, R., Dinarello, C. A., Harris, T. B., Benjamin, E. J., Au, R., Kiel, D. P., Wolf, P. A. and Seshadri, S. 2007. Inflammatory markers and the risk of Alzheimer disease: The Framingham Study. Neurology, 68: 1902-1908.
131. Tang, J. X., Baranov, D., Hammond, M., Shaw, L. M., Eckenhoff, M. F. and Eckenhoff, R. G. 2011. Human Alzheimer and inflammation biomarkers after anesthesia and surgery. Anesthesiology, 115: 727-732.
132. Tang, W., Lu, Y., Tian, Q. Y., Zhang, Y., Guo, F. J., Liu, G. Y., Syed, N. M., Lai, Y., Lin, E. A.Kong, L. 2011. The growth factor progranulin binds to TNF receptors and is therapeutic against inflammatory arthritis in mice. Science, 332: 478-484.
133. Tarkowski, E., Andreasen, N., Tarkowski, A. and Blennow, K. 2003. Intrathecal inflammation precedes development of Alzheimer's disease. Journal of Neurology, Neurosurgery and Psychiatry, 74: 1200-1205.
134. Tarkowski, E., Blennow, K., Wallin, A. and Tarkowski, A. 1999. Intracerebral production of tumor necrosis factor-alpha, a local neuroprotective agent, in Alzheimer disease and vascular dementia. Journal of Clinical Immunology, 19: 223-230.
135. Terrando, N., Rei Fidalgo, A., Vizcaychipi, M., Cibelli, M., Ma, D., Monaco, C., Feldmann, M. and Maze, M. 2010. The impact of IL-1 modulation on the development of lipopolysaccharide-induced cognitive dysfunction. Critical Care, 14: R88
136. Teunissen, C. E., van Boxtel, M. P., Bosma, H., Bosmans, E., Delanghe, J., De Bruijn, C., Wauters, A., Maes, M., Jolles, J., Steinbusch, H. W. and de Vente, J. 2003. Inflammation markers in relation to cognition in a healthy aging population. Journal of Neuroimmunology, 134: 142-150.
137. Ton, T. G., Heckbert, S. R., Longstreth, W. T. Jr, Rossing, M. A., Kukull, W. A., Franklin, G. M., Swanson, P. D., Smith-Weller, T. and Checkoway, H. 2006. Nonsteroidal anti-inflammatory drugs and risk of Parkinson's disease. Movement Disorders, 21: 964-969.
138. Trollor, J. N., Smith, E., Baune, B. T., Kochan, N. A., Campbell, L., Samaras, K., Crawford, J., Brodaty, H. and Sachdev, P. 2010. Systemic Inflammation Is Associated with MCI and Its Subtypes: The Sydney Memory and Aging Study. Dementia and Geriatric Cognitive Disorders, 30: 569-578.
139. Vehmas, A. K., Kawas, C. H., Stewart, W. F. and Troncoso, J. C. 2003. Immune reactive cells in senile plaques and cognitive decline in Alzheimer's disease. Neurobiology of Aging, 24: 321-331.
140. Villeda, S. A., Luo, J., Mosher, K. I., Zou, B., Britschgi, M., Bieri, G., Stan, T. M., Fainberg, N., Ding, Z.Eggel, A. 2011. The ageing systemic milieu negatively regulates neurogenesis and cognitive function. Nature, 477: 90-94.
141. Vitkovic, L., Bockaert, J. and Jacque, C. 2000. 'Inflammatory' cytokines: Neuromodulators in normal brain?. Journal of Neurochemistry, 74: 457-471.
142. Wahner, A. D., Bronstein, J. M., Bordelon, Y. M. and Ritz, B. 2007. Nonsteroidal anti-inflammatory drugs may protect against Parkinson disease. Neurology, 69: 1836-1842.
143. Weaver, J. D., Huang, M. H., Albert, M., Harris, T., Rowe, J. W. and Seeman, T. E. 2002. Interleukin-6 and risk of cognitive decline: MacArthur studies of successful aging. Neurology, 59: 371-378.
144. Wersching, H., Duning, T., Lohmann, H., Mohammadi, S., Stehling, C., Fobker, M., Conty, M., Minnerup, J., Ringelstein, E. B.Berger, K. 2010. Serum C-reactive protein is linked to cerebral microstructural integrity and cognitive function. Neurology, 74: 1022-1029.
145. Weuve, J., Ridker, P. M., Cook, N. R., Buring, J. E. and Grodstein, F. 2006. High-sensitivity C-reactive protein and cognitive function in older women. Epidemiology, 17: 183-189.
146. Witlox, J., Eurelings, L. S., de Jonghe, J. F., Kalisvaart, K. J., Eikelenboom, P. and van Gool, W. A. 2010. Delirium in elderly patients and the risk of postdischarge mortality, institutionalization, and dementia: A meta-analysis. The Journal of the American Medical Association, 304: 443-451.
147. Wu, Y., Le, W. and Jankovic, J. 2011. Preclinical biomarkers of Parkinson disease. Archives of Neurology, 68: 22-30.
148. Wyss-Coray, T. and Mucke, L. 2002. Inflammation in neurodegenerative disease-A double-edged sword. Neuron, 35: 419-432.
149. Yaffe, K., Kanaya, A., Lindquist, K., Simonsick, E. M., Harris, T., Shorr, R. I., Tylavsky, F. A. and Newman, A. B. 2004. The metabolic syndrome, inflammation, and risk of cognitive decline. The Journal of the American Medical Association, 292: 2237-2242.
150. Yaffe, K., Lindquist, K., Penninx, B. W., Simonsick, E. M., Pahor, M., Kritchevsky, S., Launer, L., Kuller, L., Rubin, S. and Harris, T. 2003. Inflammatory markers and cognition in well-functioning African-American and white elders. Neurology, 61: 76-80.
151. Yirmiya, R. and Goshen, I. 2011. Immune modulation of learning, memory, neural plasticity and neurogenesis. Brain, Behavior, & Immunity, 25: 181-213.
152. Zhu, J., Quyyumi, A. A., Norman, J. E., Csako, G., Waclawiw, M. A., Shearer, G. M. and Epstein, S. E. 2000. Effects of total pathogen burden on coronary artery disease risk and C-reactive protein levels. The American Journal of Cardiology, 85: 140-146.
153. Ziv, Y., Ron, N., Butovsky, O., Landa, G., Sudai, E., Greenberg, N., Cohen, H., Kipnis, J. and Schwartz, M. 2006. Immune cells contribute to the maintenance of neurogenesis and spatial learning abilities in adulthood. Natrue Neuroscience, 9: 268-275.